We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+1.17%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$47.1B
AUM Growth
-$899M
(-1.9%)
Cap. Flow
-$982M
Cap. Flow
% of AUM
-2.08%
Top 10 Holdings %
Top 10 Hldgs %
35.43%
Holding
967
New
122
Increased
219
Reduced
464
Closed
97
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$250M |
| 2 |
Starbucks
SBUX
|
+$152M |
| 3 |
CERN
Cerner Corp
CERN
|
+$122M |
| 4 |
Colgate-Palmolive
CL
|
+$87.1M |
| 5 |
Procter & Gamble
PG
|
+$77.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$456M |
| 2 |
Cisco
CSCO
|
+$392M |
| 3 |
Analog Devices
ADI
|
+$151M |
| 4 |
United Parcel Service
UPS
|
+$148M |
| 5 |
VAR
Varian Medical Systems, Inc.
VAR
|
+$89.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.05% |
| 2 | Consumer Discretionary | 15.92% |
| 3 | Financials | 12.69% |
| 4 | Healthcare | 12.47% |
| 5 | Communication Services | 9.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HK
526
DELISTED
Halcon Resources Corporation
HK
| $1.55M | ﹤0.01% |
318,595
| – | – |
|
|
RDS.B
527
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
| $1.21M | ﹤0.01% |
18,381
-1,607
| -8% | -$108K |
|
528
Aptiv
APTV
$10.3B
| $1.17M | ﹤0.01% |
13,806
-10,293
| -43% | -$934K |
|
529
GSK
GSK
$106B
| $1.15M | ﹤0.01% |
23,502
-500
| -2% | -$23.3K |
|
530
Crown Holdings
CCK
$13.1B
| $1.13M | ﹤0.01% |
22,314
| – | – |
|
|
XIFR
531
XPLR Infrastructure LP
XIFR
$1.08B
| $1.09M | ﹤0.01% |
27,330
-2,573
| -9% | -$104K |
|
532
Morgan Stanley
MS
$340B
| $958K | ﹤0.01% |
17,756
-13,343
| -43% | -$739K |
|
|
PPL
533
PPL Corp
PPL
$26.7B
| $932K | ﹤0.01% |
32,962
+3,483
| +12% | +$104K |
|
534
Core Laboratories
CLB
$521M
| $915K | ﹤0.01% |
8,456
+572
| +7% | +$63.3K |
|
535
Hershey
HSY
$36.6B
| $816K | ﹤0.01% |
8,241
+3,370
| +69% | +$348K |
|
536
Ryman Hospitality Properties
RHP
$7.63B
| $786K | ﹤0.01% |
10,147
-2,014
| -17% | -$147K |
|
537
MPLX
MPLX
$59.7B
| $739K | ﹤0.01% |
22,356
-475
| -2% | -$17K |
|
538
AbbVie
ABBV
$435B
| $701K | ﹤0.01% |
7,404
-3,684
| -33% | -$405K |
|
539
International Paper
IP
$22B
| $692K | ﹤0.01% |
13,670
-1,346
| -9% | -$74.8K |
|
540
Principal Financial Group
PFG
$24.3B
| $578K | ﹤0.01% |
+9,497
| New | +$625K |
|
|
HES.PRA
541
DELISTED
Hess Corporation
HES.PRA
| $533K | ﹤0.01% |
+9,760
| New | +$571K |
|
|
MIC
542
DELISTED
Macquarie Infrastructure Holdings, LLC
MIC
| $488K | ﹤0.01% |
13,221
+1,760
| +15% | +$94.8K |
|
|
NIHD
543
DELISTED
NII Holdings, Inc. Common Stock
NIHD
| $407K | ﹤0.01% |
192,865
| – | – |
|
544
Allison Transmission
ALSN
$9.82B
| $381K | ﹤0.01% |
9,749
+7,950
| +442% | +$330K |
|
545
Ralph Lauren
RL
$23.6B
| $369K | ﹤0.01% |
3,301
+2,598
| +370% | +$281K |
|
546
Caterpillar
CAT
$387B
| $359K | ﹤0.01% |
2,438
-1,324
| -35% | -$209K |
|
547
CVR Energy
CVI
$3.13B
| $349K | ﹤0.01% |
+11,556
| New | +$388K |
|
548
Quest Diagnostics
DGX
$26.3B
| $348K | ﹤0.01% |
3,472
+762
| +28% | +$78K |
|
549
Las Vegas Sands
LVS
$29.6B
| $340K | ﹤0.01% |
4,723
+49
| +1% | +$3.59K |
|
550
J.M. Smucker
SJM
$12.8B
| $340K | ﹤0.01% |
2,740
-21
| -0.8% | -$2.62K |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q1 2018 Portfolio in Review
As of Q1 2018, Loomis, Sayles & Company held 967 positions worth $47.1B, down 1.9% from $48B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Loomis, Sayles & Company's Q1 2018 filing shows 122 new, 219 increased, 464 reduced and 97 closed positions. Its largest new stake was BioMarin Pharmaceuticals: 870,638 shares worth $70.6M. The largest sale was Amazon, an estimated $456M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 18% a quarter earlier, followed by Consumer Discretionary and Financials.
- Loomis, Sayles & Company's largest Q1 2018 buy was BioMarin Pharmaceuticals: 870,638 shares worth $70.6M.
- Loomis, Sayles & Company added most to Regeneron Pharmaceuticals in Q1 2018, an estimated $250M increase.
- Loomis, Sayles & Company's biggest Q1 2018 reduction was Amazon, cutting an estimated $456M.
- Loomis, Sayles & Company fully exited Analog Devices in Q1 2018, selling an estimated $151M.
- Loomis, Sayles & Company's ten largest holdings make up 35% of its $47.1B portfolio in Q1 2018.
- Loomis, Sayles & Company opened 122 new positions and closed 97 in Q1 2018.
- Loomis, Sayles & Company's portfolio value fell 1.9% quarter-over-quarter to $47.1B.
Based on Loomis, Sayles & Company's 13F filing for Q1 2018, filed 11 May 2018.